3,750 Shares in Stryker Co. (NYSE:SYK) Acquired by PFW Advisors LLC

PFW Advisors LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,750 shares of the medical technology company's stock, valued at approximately $1,350,000.

Several other institutional investors also recently bought and sold shares of SYK. Dunhill Financial LLC boosted its position in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR boosted its position in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the third quarter valued at about $36,000. HBW Advisory Services LLC acquired a new position in Stryker during the 3rd quarter worth approximately $42,000. Finally, Hara Capital LLC purchased a new stake in shares of Stryker during the third quarter valued at approximately $42,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

NYSE:SYK traded down $4.70 during trading hours on Monday, reaching $360.96. 1,400,728 shares of the company's stock were exchanged, compared to its average volume of 1,302,026. The company has a market capitalization of $137.60 billion, a P/E ratio of 38.69, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. Stryker Co. has a 12 month low of $307.23 and a 12 month high of $398.20. The business's 50-day simple moving average is $375.40 and its two-hundred day simple moving average is $357.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same period last year, the company posted $2.46 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. Sell-side analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. This is a positive change from Stryker's previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker's dividend payout ratio is 36.01%.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SYK shares. Robert W. Baird lifted their target price on Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Truist Financial lifted their price target on shares of Stryker from $380.00 to $409.00 and gave the stock a "hold" rating in a research note on Wednesday, December 18th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Tuesday, January 7th. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Finally, Barclays increased their price target on shares of Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.